HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 280, Issue 24, 22788-22792, June 17, 2005

This Article Abstract Full Text (PDF) All Versions of this Article: 280/24/22788    most recent C500138200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhao, R. Articles by Zhao, Z. J. Search for Related Content PubMed PubMed Citation Articles by Zhao, R. Articles by Zhao, Z. J. Social Bookmarking                      What's this?

Identification of an Acquired JAK2 Mutation in Polycythemia Vera^*

Runxiang Zhao, Shu Xing, Zhe Li, Xueqi Fu, Qingshan Li, Sanford B. Krantz, and Zhizhuang Joe Zhao¶

From the Hematology/Oncology Division, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee 37232 and the Edmond H. Fischer Signal Transduction Laboratory, College of Life Sciences, Jilin University, Changchun 130023, China

Received for publication, March 25, 2005 , and in revised form, April 26, 2005.

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Polycythemia vera (PV) is a human clonal hematological disorder. The molecular etiology of the disease has not been identified. PV hematopoietic progenitor cells exhibit hypersensitivity to growth factors and cytokines, suggesting possible abnormalities in protein-tyrosine kinases and phosphatases. By sequencing the entire coding regions of cDNAs of candidate enzymes, we identified a G:C T:A point mutation of the JAK2 tyrosine kinase in 20 of 24 PV blood samples but none in 12 normal samples. The mutation has varying degrees of heterozygosity and is apparently acquired. It changes conserved Val⁶¹⁷ to Phe in the pseudokinase domain of JAK2 that is known to have an inhibitory role. The mutant JAK2 has enhanced kinase activity, and when overexpressed together with the erythropoietin receptor in cells, it caused hyperactivation of erythropoietin-induced cell signaling. This gain-of-function mutation of JAK may explain the hypersensitivity of PV progenitor cells to growth factors and cytokines. Our study thus defines a molecular defect of PV.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Polycythemia vera (PV)¹ is a clonal myeloproliferative disorder characterized by increased production of red cells, granulocytes, and platelets (1–3). It mainly affects people between 40 and 60 years of age with an annual incidence of about 14 per million in the population. Thus far there is no effective cure for the disease. Phlebotomy is the mainstay of treatment for the disease, and hydroxyurea, interferon-, and anagrelide drug therapies and ³²P radiation therapy have commonly been used (3). The mortality rate is high if the disease is untreated or is associated with leukemia. Despite extensive studies in recent years, the molecular etiology of PV remains unknown.

A major feature of PV is that hematopoietic progenitors in patients display hypersensitive responses to many growth factors and cytokines (1–3). Despite these abnormal responses, the numbers of receptors for the growth factors and cytokines on the surface of these cells are normal, suggesting a primary defect in a shared signaling pathway in these cells. Tyrosine phosphorylation is a fundamental regulatory mechanism for cell growth and development, and this process is controlled by coordinate actions of protein-tyrosine kinases (PTKs) and phosphatases (PTPs) (4). Both families of enzymes have highly diverse structures and functions. Their activities are tightly regulated under normal conditions, and deregulation of the enzymes produces human diseases. According to the human genomic data base, there are about 90 PTKs and 38 phosphotyrosine-specific PTPs (5–7). Both mutation of PTKs and PTPs have been implicated in human cancers. Recent studies using a large scale sequencing-based approach revealed that PTK and PTP genes are mutated more often in human cancers than previously anticipated. A minimum of 30% of colorectal cancers contains at least one mutation in PTKs, and 26% of them has a mutation in PTPs (8, 9). It is highly expected that mutations of PTKs and PTPs may also be a major manifestation of other types of malignancies such as PV.

In earlier studies, we found that PV erythroid progenitor cells contain a hyperactive PTP that corresponds to PTP-MEG2 (10, 11). However, this abnormality is caused by altered distribution of the enzyme rather than a mutation in its primary structure, suggesting that PTP-MEG2 is not the primary cause of the disease. Considering the general importance PTKs and PTPs and the feature of PV hematopoietic progenitor cells, we have performed a large scale DNA sequencing analysis of a number of candidate PTPs and PTKs. Here we report the identification of a JAK2 mutation in a majority of the PV samples. We have further demonstrated the JAK2 mutant has a gain-of-function feature.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Materials—Polyclonal antibodies against JAK2 and the erythropoietin receptor (EPOR) were from Santa Cruz Biotechnology. Polyclonal antibodies against regular and phosphorylated forms of STAT5, ERK1/2, and Akt were from Cell Signaling Technology. Peripheral blood samples were obtained from healthy volunteers and PV patients. Approval was obtained from the Vanderbilt University institutional review board for these studies. All of the PV patients met the established criteria for PV (3). The blood samples (usually 10 ml for isolation of mononuclear cells and 400 ml for purification of erythroid colony-forming cells) were collected in heparin at a final concentration of 20 units/ml. Light density mononuclear cells were collected by centrifugation on Ficoll (1.077 g/ml) following the standard protocol. Erythroid colony-forming cells were purified as described previously (10).

PCR and Sequencing Analysis—Total RNAs were isolated from peripheral blood mononuclear cells and erythroid colony-forming cells by using the TRIzol reagent (Invitrogen), and genomic DNAs were extracted by phenol/chloroform after proteinase K digestion following standard techniques. First strand cDNAs were prepared by reverse transcription of total RNAs with random primers. For amplification of the JAK2 cDNA, the primers used were 5'-CCTCCCGCGACGGCAAATGTTCT-3' and 5'-CTTTGTTCTGTAAATCTACTTTGGTCTCAG-3' for initial PCR and 5'-TGCATGGGAATGGCCTGCCTTAC-3' and 5'-CTTTCATCCAGCCATGTTATCCCTTA-3' for nested PCR. For amplification of the JAK2 genomic DNA, the PCR primers were 5'-TCTTGTTCCTACTTCGTTCTCCATC-3' and 5'TATTGTTTGGGCATTGTAACCTTCT-3', which cover exons 13 and 14 of the JAK2 gene. PCR was performed with high fidelity DNA polymerase Pfu-ultra (Stratagene) or Phusion (MJ Bioworks, Inc.). The PCR products were purified from agarose gels and sequenced directly using the ABI 3730xl DNA analyzer at the Vanderbilt-Ingram Cancer Center.

JAK2 Activity Assays—To make a substrate for JAK kinase activity assays, we expressed a GST fusion protein containing a peptide segment corresponding to amino acid residues 883–1132 at the C-terminal end of JAK2. This portion of JAK2 contains the autophosphorylation sites Tyr¹⁰⁰⁷ and Tyr¹⁰⁰⁸. The fusion protein, designated GST-JAK2CT, was purified from Escherichia coli cells by using glutathione-Sepharose columns. Wild type JAK2 and the JAK2^V617F mutant were cloned into the pcDNA3 vector (Invitrogen) for expression in HeLa cells. Upon transfection with the FuGENE 6 transfection reagent (Roche Applied Science), cells were lysed in a buffer containing 50 mM -glycerophosphate (pH 7.3), 5 mM EDTA, 1 mM EGTA, 5 mM -mercaptoethanol, 1% Triton X-100, 0.1 M NaCl, and a protease inhibitor mixture (Roche Applied Science). The JAK2 and JAK2^V617F enzymes were immunopurified from the cell extracts by using anti-JAK2 antibodies immobilized on agarose. The kinase assay system contained JAK2 immunoprecipitates, 0.1 mg/ml GST-JAK2CT, 25 mM Tris-HCl (pH 7.5), 10 mM MgCl₂, 50 µM ATP, and 2 mM dithiothreitol. The reactions were allowed to proceed at room temperature for 20 min and then stopped by addition of the SDS gel sample buffer. Tyrosine phosphorylation of GST-JAK2CT was determined by Western blotting analysis with an anti-phosphotyrosine antibody.

Co-expression of JAK2 and JAK2^V617F with EPOR and EPO Signaling Assays—HeLa cells were co-transfected with pRc/CMV-EPOR and pcDNA3-JAK2 or pcDNA3-JAK2^V617F in the presence of the FuGENE 6 transfection reagent. After 40 h, the cells were serum-starved for 4 h and then treated with 40 units/ml EPO (Amgen) for different time periods. The stimulation was stopped by washing the cells with cold phosphate-buffered saline, and the cells were extracted as described above. For Western blotting analyses, protein extracts containing equal amounts of total proteins were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were probed with various primary antibodies that were detected by using the enhanced chemiluminescence (ECL) system with horseradish peroxidase-conjugated secondary antibodies.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Identification of a JAK2 Mutation in PV—Initially, we hypothesized that PV might be caused by mutations of PTKs and/or PTPs. To identify the mutations, our basic strategy was to sequence the entire coding regions of a number of PTPs and PTKs selected based on their known involvement in erythropoiesis. For PTPs, we analyzed SHP-1, SHP-2, TC-PTP, RPTP, DEP, PTP-MEG1, PTP-MEG2, and CD45. These are the major PTPs identified in erythroid colony-forming cells (11). For PTKs, we chose members of the Src, Abl, JAK, and platelet-derived growth factor (PDGF) receptor families. We isolated total RNAs from peripheral blood mononuclear cells and purified erythroid colony-forming cells. Upon synthesis of first strand cDNAs by reverse transcription, PCR was performed with primers corresponding to the 5' and 3' ends of the coding regions of candidate PTPs and PTKs. For samples that failed to yield products in the first PCR, nested PCR was performed with a set of inner primers. To avoid mutations caused by PCR amplifications, high fidelity DNA polymerases (Pfu-ultra and Phusion) were used. Complete sequencing analyses of the PCR products revealed sporadic single nucleotide polymorphisms, point mutations, and abnormal splicing of several PTPs and PTKs (not shown) and, most importantly, defined a point mutation of JAK2 in the majority of PV samples (Fig. 1). The JAK2 mutation is a G:C T:A transversion, WHICH causes substitution of Val⁶¹⁷ by phenylalanine. At the cDNA level, we found mutations of JAK2 in 20 of 24 samples but not at all in 12 normal samples analyzed. In most cases, the mutation was heterozygous with varying proportions of the mutant JAK2 in the PCR products. In some cases, the mutant constituted only a small portion of the PCR products (15%, see PV1 in Fig. 1), whereas in three cases (e.g. PV4 in Fig. 1), nearly 100% of the PCR products corresponded to the mutant. The mutation is apparently not confined to erythroid progenitor cells, because no increase in the portion of mutant JAK2 was seen with RNAs isolated from purified erythroid colony-forming cells (data not shown), reflecting the multiple lineage feature of PV. Because the point mutation occurs somewhere in the middle of the JAK2 cDNA, it should not affect the efficiency of PCR amplification. Therefore, the ratio of wild type and mutant JAK2 PCR products should reflect the ratio of the wild type and mutant JAK2 mRNA in the original samples. We also analyzed the sequence of JAK2 at the genomic level. The mutation point is located at exon 14 of the JAK2 gene (the translation initiation codon is in exon 3). We designed PCR primers to amplify a fragment (1678 bp) of the gene covering exons 13 and 14 with an intron in between. Samples showing homozygous mutation of JAK2 at the cDNA level also gave rise to homozygous mutation with genomic DNAs. Interestingly, in all cases, the genomic DNA gave rise to significantly lower amounts of the mutant PCR products than the correspondent cDNA samples. In fact, several samples that showed low percentages of the JAK2 mutant in the PCR products with cDNAs produced hardly any mutant JAK2 PCR product with genomic DNAs (e.g. PV1 in Fig. 1). Apparently, analysis of cDNA is more sensitive in detecting the mutation of JAK2 in PV than in genomic DNAs. This is because not all hematopoietic cells express JAK2, and those expressing high levels of JAK2 mRNA are also affected by the mutant enzyme. These cells, bearing the mutant JAK2, presumably have gained an advantage to grow and thus give rise to more mRNA products without contributing much to the total genomic DNA in the blood. Altogether, the different degrees of mutation detected with both cDNAs and genomic DNAs indicate that the mutations of JAK2 in PV are not derived from germ lines but rather represent acquired events occurred in certain hematopoietic progenitor cells.

View larger version (51K): [in this window] [in a new window]   FIG. 1. Identification of JAK mutation in cDNAs and genomic DNAs. The data show sequencing of JAK2 PCR products from cDNAs (from both 5' and 3' directions) and the corresponding genomic DNAs (from 3' side only) of one normal and four PV mononuclear cell samples. The mutation point is underlined. Percentages of the mutant in the total PCR products were calculated based on the average signals of nucleotides A and C in the sequencing analysis.

View larger version (42K): [in this window] [in a new window]   FIG. 2. Structural analyses of the JAK2 mutant. Shown is a schematic structure of JAK2 together with the sequence alignment of the JAK family PTKs in the region where the V617F mutation (underlined) occurs in PV JAK2.

View larger version (58K): [in this window] [in a new window]   FIG. 3. JAK2V617F has enhanced tyrosine kinase activity. JAK2 and JAK2V617F were immunopurified from HeLa cells transfected with pcDNA3-JAK2 or JAK2V617F. Kinase activity assays were performed with GST-JAK2CT as a substrate in the presence of ATP-Mg2+. Tyrosine phosphorylation was detected by using anti-phosphotyrosine antibody (PY) and the protein levels of JAK2/JAK2V617F and GST-JAK2CT, by anti-JAK and anti-GST, respectively. IB, immunoblot.

To analyze whether JAK2^V617F produces a gain-of-function phenotype in cells, we co-expressed EPOR with JAK2 or JAK2^V617F in HeLa cells. The cells were treated or left untreated with erythropoietin, and activation of various signaling components was accessed by using phosphospecific antibodies. As expected, expression of JAK2^V617F resulted in a much high activation of STAT5, ERK1/2, and Akt than the wild type enzyme (Fig. 4). Significant activation of these signaling components was seen even in the absence of erythropoietin. These data demonstrate that JAK2^V617F causes hyperactivation of signal transduction pathways induced by EPO, which presumably is responsible for the EPO-independent growth of PV erythroid progenitor cells and the hypersensitivity of these cells to growth factors and cytokines.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
In the present study, we identified an acquired mutation of JAK2 in 83% of PV samples that we analyzed. This mutation causes replacement of a key valine residue by phenylalanine in the pseudokinase domain of JAK2 that has an inhibitory role. Structural analysis predicts gain-of-function phenotype. Our further study by overexpressing the mutant enzyme demonstrated that the mutant enzyme has enhanced kinase activity and causes hyperactivation of signal transduction pathways downstream of EPOR. We thus defined a molecular defect of the PV disease. This should have major implications in the diagnosis and treatment of PV disease. Increasing evidence has shown that tyrosine kinases are excellent targets for cancer drug therapies. JAK2 thus becomes a potential target for developing therapeutic drugs to treat PV.

View larger version (62K): [in this window] [in a new window]   FIG. 4. JAK2V617F causes hyperactivation of EPO-induced cell signaling. HeLa cells were co-transfected with EPOR and JAK2 or JAK2V617F. Cells were treated with 40 units/ml EPO for 15 min and then extracted. Cell extracts were subjected to Western blotting analyses with the indicated antibodies. Additional data indicate that the protein levels of STAT5, Akt, and ERK1/2 were not altered by the cell transfection (data not shown).

The JAK family PTKs have a unique domain structure with a kinase domain (JH1) adjacent to a pseudokinase domain (JH2) (12, 13). The JH2 domain lacks essential amino acid residues conserved in active protein kinases. The third Gly of the canonical GXGXXG motif in subdomain I is replaced by Thr; the conserved Asp in the DxxxxN motif in subdomain VIB is replaced by Ala; DFG in subdomain VII becomes DPG (see Fig. 2). The lack of these key residues would make the pseudokinase domain catalytically inactive, which has been confirmed. In fact, the pseudokinase domain plays a key regulatory role by inhibiting the kinase activity of JH1. The V617F mutation occurs on the C-terminal side of -sheet 4 in subdomain III of the pseudokinase domain, which may cause major conformational changes and thereby disrupt the inhibitory effects. This appears to be the case based on our kinase activity analyses (Fig. 3).

PV is a clonal disorder and the defect is intrinsic to the progenitor cells. The hypersensitivity of PV progenitor cells to growth factors/cytokines and the autonomous growth of some populations of erythroid progenitor cells in the absence of growth factors suggest hyperactivation of downstream signaling pathways. Indeed, an earlier study demonstrated that peripheral granulocytes from some PV patients have constitutive STAT3 DNA binding activity (27), and a recent study showed systematic increased phosphorylation of Akt/PKB in purified erythroid colony-forming cells from PV patients (28). As a signal transducer immediately downstream of EPOR, enhanced JAK2 activity due to its mutation would cause hyperactivation of further downstream signaling components, thereby causing abnormal cell growth. By co-expressing JAK2 with EPOR in a model cell line, our study has demonstrated that the JAK2 mutant indeed causes hyperactivition of signal transduction pathways induced by EPO (Fig. 4). We also expressed the JAK2 mutant in primary CD34⁺ hematopoietic progenitor cells from normal blood by using retrovirus-mediated gene transfer as described previously (11). However, this failed to produce a significant effect on the growth and development of these cells in vitro (data not shown). One possible explanation is that gain-of-function mutation of JAK2 was not sufficient to transform primary cells. This implies that other abnormalities such as loss of tumor suppressors may be associated with PV.²

	FOOTNOTES

 
^* This work was supported by Grants HL076309 (to Z. J. Z.), DK-15555 (to S. B. K.), and CA-68485 (to Vanderbilt-Ingram Cancer Center) from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ To whom correspondence should be addressed: 777 Preston Research Bldg., 2220 Pierce Ave., Nashville, TN 37232. Fax: 615-936-3853; Tel.: 615-936-1797; E-mail: joe.zhao{at}vanderbilt.edu.

¹ The abbreviations used are: PV, polycythemia vera; PTK, protein-tyrosine kinase; PTP, protein-tyrosine phosphatase; EPO, erythropoietin; EPOR, erythropoietin receptor; GST, glutathione S-transferase; STAT, signal transducers and activators of transcription; ERK, extracellular signal-regulated kinase; JAK, Janus kinase; JH, JAK homology; SH, Src homology; IR, inhibitory region; IL, interleukin.

² Four articles reporting similar findings have recently been published or are currently in press (29–32).

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Green, A. R. (1996) Lancet 347, 844–845[CrossRef][Medline] [Order article via Infotrieve]
2. Prchal, J. F., and Prchal, J. T. (1999) Curr. Opin. Hematol. 6, 100–109[CrossRef][Medline] [Order article via Infotrieve]
3. Spivak, J. L. (2002) Blood 100, 4272–4290[Free Full Text]
4. Hunter, T. (2000) Cell 100, 113–127[CrossRef][Medline] [Order article via Infotrieve]
5. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) Science 298, 1912–1934[Abstract/Free Full Text]
6. Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., and Mustelin, T. (2004) Cell 117, 699–711[CrossRef][Medline] [Order article via Infotrieve]
7. Andersen, J. N., Jansen, P. G., Echwald, S. M., Mortensen, O. H., Fukada, T., Del Vecchio, R., Tonks, N. K., and Moller, N. P. (2004) FASEB J. 18, 8–30[Abstract/Free Full Text]
8. Bardelli, A., Parsons, D. W., Silliman, N., Ptak, J., Szabo, S., Saha, S., Markowitz, S., Willson, J. K., Parmigiani, G., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2003) Science 300, 949[Free Full Text]
9. Wang, Z., Shen, D., Parsons, D. W., Bardelli, A., Sager, J., Szabo, S., Ptak, J., Silliman, N., Peters, B. A., van der Heijden, M. S., Parmigiani, G., Yan, H., Wang, T. L., Riggins, G., Powell, S. M., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2004) Science 304, 1164–1166[Abstract/Free Full Text]
10. Sui, X., Krantz, S. B., and Zhao, Z. (1997) Blood 90, 651–657[Abstract/Free Full Text]
11. Xu, M. J., Sui, X., Zhao, R., Dai, C., Krantz, S. B., and Zhao, Z. J. (2003) Blood 102, 4354–4360[Abstract/Free Full Text]
12. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. (1994) Science 264, 1415–1421[Abstract/Free Full Text]
13. Ihle, J. N. (1995) Adv. Immunol. 6, 1–35
14. Girault, J. A., Labesse, G., Mornon J. P., and Callebaut, I. (1998) Mol. Med. 4, 751–769[Medline] [Order article via Infotrieve]
15. Hanks, S. K., and Hunter, T. (1995) FASEB J. 9, 576–596[Abstract]
16. Hanks, S. K. (2003) Genome Biol. 2003, 4: 111[CrossRef][Medline] [Order article via Infotrieve]
17. Saharinen, P., Vihinen, M., and Silvennoinen, O. (2003) Mol. Biol. Cell 14, 1448–1459[Abstract/Free Full Text]
18. Ward, A. C., Touw, I., and Yoshimura, A. (2000) Blood 95, 19–29[Free Full Text]
19. Kisseleva, T., Bhattacharya, S., Braunstein, J., and Schindler, C. W. (2002) Gene 285, 1–24[CrossRef][Medline] [Order article via Infotrieve]
20. Verma, A., Kambhampati, S., Parmar, S., and Platanias, L. C. (2003) Cancer Metastasis Rev. 22, 423–434[CrossRef][Medline] [Order article via Infotrieve]
21. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., and Pfeffer, K. (1998) Cell 93, 397–409[CrossRef][Medline] [Order article via Infotrieve]
22. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J. C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., Grosveld, G., and Ihle, J. N. (1998) Cell 93, 385–395[CrossRef][Medline] [Order article via Infotrieve]
23. Wu, H., Liu, X., Jaenisch, R., and Lodish, H. F. (1995) Cell 83, 59–67[CrossRef][Medline] [Order article via Infotrieve]
24. Krantz, S. B. (1991) Blood 77, 419–434[Free Full Text]
25. Sui, X., Krantz, S. B., You, M., and Zhao, Z. (1998) Blood 92, 1142–1149[Abstract/Free Full Text]
26. Bench, A. J., Nacheva, E. P., Champion, K. M., and Green, A. R. (1998) Baillieres Clin. Haematol. 11, 819–848[CrossRef][Medline] [Order article via Infotrieve]
27. Roder, S., Steimle, C., Meinhardt, G., and Pahl, H. L. (2001) Exp. Hematol. 29, 694–702[CrossRef][Medline] [Order article via Infotrieve]
28. Dai, C., Chung, I. J., and Krantz, S. B. (2005) Exp. Hematol. 33, 152–158[CrossRef][Medline] [Order article via Infotrieve]
29. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., Scott, M. A., Erber, W. N., and Green, A. R. (2005) Lancet 365, 1054–1061[Medline] [Order article via Infotrieve]
30. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., Adelsperger, J., Koo, S., Lee, J. C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R. A., Tefferi, A., Griffin, J. D., Eck, M. J., Sellers, W. R., Meyerson, M., Golub, T. R., Lee, S. J., and Gilliland, D. G. (2005) Cancer Cell 7, 387–397[CrossRef][Medline] [Order article via Infotrieve]
31. James, C., Ugo, V., Le Couedic, J. P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J. L., Constantinescu, S. N., Casadevall, N., and Vainchenker, W. (2005) Nature, 434, 1144–1148[CrossRef][Medline] [Order article via Infotrieve]
32. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., and Skoda, R. C. (2005) N. Engl. J. Med., 352, 1779–1790[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				O. Abdel-Wahab, A. Mullally, C. Hedvat, G. Garcia-Manero, J. Patel, M. Wadleigh, S. Malinge, J. Yao, O. Kilpivaara, R. Bhat, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Blood, July 2, 2009; 114(1): 144 - 147. [Abstract] [Full Text] [PDF]

				S. Gery, Q. Cao, S. Gueller, H. Xing, A. Tefferi, and H. P. Koeffler Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F J. Leukoc. Biol., June 1, 2009; 85(6): 957 - 965. [Abstract] [Full Text] [PDF]

				J. Elliott, Y. Suessmuth, L. M. Scott, K. Nahlik, M. F. McMullin, S. N. Constantinescu, A. R. Green, and J. A. Johnston SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases Haematologica, April 1, 2009; 94(4): 576 - 580. [Abstract] [Full Text] [PDF]

				I. Rapado, S. Grande, E. Albizua, R. Ayala, J.-A. Hernandez, M. Gallardo, F. Gilsanz, and J. Martinez-Lopez High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations: A Diagnostic Tool for Myeloproliferative Neoplasms J. Mol. Diagn., March 1, 2009; 11(2): 155 - 161. [Abstract] [Full Text] [PDF]

				A. Zeuner, F. Pedini, F. Francescangeli, M. Signore, G. Girelli, A. Tafuri, and R. De Maria Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells Blood, February 12, 2009; 113(7): 1522 - 1525. [Abstract] [Full Text] [PDF]

				N. Fourouclas, J. Li, D. C. Gilby, P. J. Campbell, P. A. Beer, E. M. Boyd, A. C. Goodeve, D. Bareford, C. N. Harrison, J. T. Reilly, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders Haematologica, November 1, 2008; 93(11): 1635 - 1644. [Abstract] [Full Text] [PDF]

				A. V. Jones, N. C.P. Cross, H. E. White, A. R. Green, and L. M. Scott Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis Haematologica, October 1, 2008; 93(10): 1560 - 1564. [Abstract] [Full Text] [PDF]

				I. Plo, M. Nakatake, L. Malivert, J.-P. de Villartay, S. Giraudier, J.-L. Villeval, L. Wiesmuller, and W. Vainchenker JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders Blood, August 15, 2008; 112(4): 1402 - 1412. [Abstract] [Full Text] [PDF]

				J. L. Spivak and R. T. Silver The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal Blood, July 15, 2008; 112(2): 231 - 239. [Full Text] [PDF]

				M. Gakovic, J. Ragimbeau, V. Francois, S. N. Constantinescu, and S. Pellegrini The Stat3-activating Tyk2 V678F Mutant Does Not Up-regulate Signaling through the Type I Interferon Receptor but Confers Ligand Hypersensitivity to a Homodimeric Receptor J. Biol. Chem., July 4, 2008; 283(27): 18522 - 18529. [Abstract] [Full Text] [PDF]

				S. G. Olthof, S. Fatrai, A. L. Drayer, M. R. Tyl, E. Vellenga, and J. J. Schuringa Downregulation of Signal Transducer and Activator of Transcription 5 (STAT5) in CD34+ Cells Promotes Megakaryocytic Development, Whereas Activation of STAT5 Drives Erythropoiesis Stem Cells, July 1, 2008; 26(7): 1732 - 1742. [Abstract] [Full Text] [PDF]

				S. Xing, T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice Blood, May 15, 2008; 111(10): 5109 - 5117. [Abstract] [Full Text] [PDF]

				A. Dusa, J. Staerk, J. Elliott, C. Pecquet, H. A. Poirel, J. A. Johnston, and S. N. Constantinescu Substitution of Pseudokinase Domain Residue Val-617 by Large Non-polar Amino Acids Causes Activation of JAK2 J. Biol. Chem., May 9, 2008; 283(19): 12941 - 12948. [Abstract] [Full Text] [PDF]

				D. B. Lipka, L. S. Hoffmann, F. Heidel, B. Markova, M.-C. Blum, F. Breitenbuecher, S. Kasper, T. Kindler, R. L. Levine, C. Huber, et al. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells Mol. Cancer Ther., May 1, 2008; 7(5): 1176 - 1184. [Abstract] [Full Text] [PDF]

				S. Li, R. Kralovics, G. De Libero, A. Theocharides, H. Gisslinger, and R. C. Skoda Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations Blood, April 1, 2008; 111(7): 3863 - 3866. [Abstract] [Full Text] [PDF]

				G. Wernig, J. R. Gonneville, B. J. Crowley, M. S. Rodrigues, M. M. Reddy, H. E. Hudon, C. Walz, A. Reiter, K. Podar, Y. Royer, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes Blood, April 1, 2008; 111(7): 3751 - 3759. [Abstract] [Full Text] [PDF]

				K. Ohyashiki, T. Kiguchi, Y. Ito, A. Gotoh, T. Tauchi, K. Miyazawa, Y. Kimura, H. Hisatomi, and J. H. Ohyashiki Isolated Erythrocythemia: A Distinct Entity or a Sub-type of Polycythemia Vera? Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 230 - 232. [Full Text] [PDF]

				L. Teofili, R. Foa, F. Giona, and L. M. Larocca Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients? Haematologica, February 1, 2008; 93(2): 169 - 172. [Full Text] [PDF]

				S. Verstovsek, T. Manshouri, A. Quintas-Cardama, D. Harris, J. Cortes, F. J. Giles, H. Kantarjian, W. Priebe, and Z. Estrov WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation Clin. Cancer Res., February 1, 2008; 14(3): 788 - 796. [Abstract] [Full Text] [PDF]

				G. Kirsammer, S. Jilani, H. Liu, E. Davis, S. Gurbuxani, M. M. Le Beau, and J. D. Crispino Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome Blood, January 15, 2008; 111(2): 767 - 775. [Abstract] [Full Text] [PDF]

				R. L. Levine and M. Heaney New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia Hematology, January 1, 2008; 2008(1): 76 - 82. [Abstract] [Full Text] [PDF]

				M. J. Percy, L. M. Scott, W. N. Erber, C. N. Harrison, J. T. Reilly, F. G.C. Jones, A. R. Green, and M. F. McMullin The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels Haematologica, December 1, 2007; 92(12): 1607 - 1614. [Abstract] [Full Text] [PDF]

				L. Teofili, F. Giona, M. Martini, T. Cenci, F. Guidi, L. Torti, G. Palumbo, A. Amendola, G. Leone, R. Foa, et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia Blood, November 1, 2007; 110(9): 3384 - 3386. [Abstract] [Full Text] [PDF]

				G. L. Chen and J. T. Prchal X-linked clonality testing: interpretation and limitations Blood, September 1, 2007; 110(5): 1411 - 1419. [Abstract] [Full Text] [PDF]

				M. A. Vickers JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year, explaining age of onset by a single rate-limiting mutation Blood, September 1, 2007; 110(5): 1675 - 1680. [Abstract] [Full Text] [PDF]

				L. Teofili, M. Martini, T. Cenci, G. Petrucci, L. Torti, S. Storti, F. Guidi, G. Leone, and L. M. Larocca Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation Blood, July 1, 2007; 110(1): 354 - 359. [Abstract] [Full Text] [PDF]

				G. Finazzi and T. Barbui How I treat patients with polycythemia vera Blood, June 15, 2007; 109(12): 5104 - 5111. [Abstract] [Full Text] [PDF]

				M. B. Hookham, J. Elliott, Y. Suessmuth, J. Staerk, A. C. Ward, W. Vainchenker, M. J. Percy, M. F. McMullin, S. N. Constantinescu, and J. A. Johnston The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3 Blood, June 1, 2007; 109(11): 4924 - 4929. [Abstract] [Full Text] [PDF]

				L. Teofili, F. Giona, M. Martini, T. Cenci, F. Guidi, L. Torti, G. Palumbo, A. Amendola, R. Foa, and L. M. Larocca Markers of Myeloproliferative Diseases in Childhood Polycythemia Vera and Essential Thrombocythemia J. Clin. Oncol., March 20, 2007; 25(9): 1048 - 1053. [Abstract] [Full Text] [PDF]

				Z. Li, M. Xu, S. Xing, W. T. Ho, T. Ishii, Q. Li, X. Fu, and Z. J. Zhao Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth J. Biol. Chem., February 9, 2007; 282(6): 3428 - 3432. [Abstract] [Full Text] [PDF]

				E. C. Wolstencroft, K. Hanlon, L. W. Harries, G. R. Standen, A. Sternberg, and S. Ellard Development of a Quantitative Real-Time Polymerase Chain Reaction Assay for the Detection of the JAK2 V617F Mutation J. Mol. Diagn., February 1, 2007; 9(1): 42 - 46. [Abstract] [Full Text] [PDF]

				L. M. Scott, W. Tong, R. L. Levine, M. A. Scott, P. A. Beer, M. R. Stratton, P. A. Futreal, W. N. Erber, M. F. McMullin, C. N. Harrison, et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis N. Engl. J. Med., February 1, 2007; 356(5): 459 - 468. [Abstract] [Full Text] [PDF]

				R. Skoda The Genetic Basis of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 1 - 10. [Abstract] [Full Text] [PDF]

				X. Xu, Q. Zhang, J. Luo, S. Xing, Q. Li, S. B. Krantz, X. Fu, and Z. J. Zhao JAK2V617F: prevalence in a large Chinese hospital population Blood, January 1, 2007; 109(1): 339 - 342. [Abstract] [Full Text] [PDF]

				P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF]

				P. J. Campbell, E. J. Baxter, P. A. Beer, L. M. Scott, A. J. Bench, B. J. P. Huntly, W. N. Erber, R. Kusec, T. S. Larsen, S. Giraudier, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation Blood, November 15, 2006; 108(10): 3548 - 3555. [Abstract] [Full Text] [PDF]

				T. Ishii, E. Bruno, R. Hoffman, and M. Xu Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera Blood, November 1, 2006; 108(9): 3128 - 3134. [Abstract] [Full Text] [PDF]

				Z. Xiong, E. Liu, Y. Yan, R. T. Silver, F. Yang, I. H. Chen, Y. Chen, S. Verstovsek, H. Wang, J. Prchal, et al. An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Antitumor Humoral Immune Reactions J. Immunol., October 1, 2006; 177(7): 4907 - 4916. [Abstract] [Full Text] [PDF]

				L. M. Scott, M. A. Scott, P. J. Campbell, and A. R. Green Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia Blood, October 1, 2006; 108(7): 2435 - 2437. [Abstract] [Full Text] [PDF]

				J. H. Kurzer, P. Saharinen, O. Silvennoinen, and C. Carter-Su Binding of SH2-B Family Members within a Potential Negative Regulatory Region Maintains JAK2 in an Active State. Mol. Cell. Biol., September 1, 2006; 26(17): 6381 - 6394. [Abstract] [Full Text] [PDF]

				D. P. Steensma JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2006; 8(4): 397 - 411. [Abstract] [Full Text] [PDF]

				C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek Advances in the Therapy of Chronic Idiopathic Myelofibrosis Oncologist, September 1, 2006; 11(8): 929 - 943. [Abstract] [Full Text] [PDF]

				R. Kralovics, S.-S. Teo, S. Li, A. Theocharides, A. S. Buser, A. Tichelli, and R. C. Skoda Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders Blood, August 15, 2006; 108(4): 1377 - 1380. [Abstract] [Full Text] [PDF]

				T. Horn, M. Kremer, T. Dechow, W. M. Pfeifer, B. Geist, M. Perker, J. Duyster, L. Quintanilla-Martinez, and F. Fend Detection of the Activating JAK2 V617F Mutation in Paraffin-Embedded Trephine Bone Marrow Biopsies of Patients with Chronic Myeloproliferative Diseases J. Mol. Diagn., July 1, 2006; 8(3): 299 - 304. [Abstract] [Full Text] [PDF]

				C. Walz, B. J. Crowley, H. E. Hudon, J. L. Gramlich, D. S. Neuberg, K. Podar, J. D. Griffin, and M. Sattler Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition J. Biol. Chem., June 30, 2006; 281(26): 18177 - 18183. [Abstract] [Full Text] [PDF]

				A. I. Schafer Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia Blood, June 1, 2006; 107(11): 4214 - 4222. [Abstract] [Full Text] [PDF]

				R. T. Chung, A. J. Iafrate, P. C. Amrein, D. V. Sahani, and J. Misdraji Case 15-2006 -- A 46-Year-Old Woman with Sudden Onset of Abdominal Distention N. Engl. J. Med., May 18, 2006; 354(20): 2166 - 2175. [Full Text] [PDF]

				R. L. Levine, C. Belisle, M. Wadleigh, D. Zahrieh, S. Lee, P. Chagnon, D. G. Gilliland, and L. Busque X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis Blood, May 15, 2006; 107(10): 4139 - 4141. [Abstract] [Full Text] [PDF]

				H. Walczak Polycythemia vera erythroblasts: too tough to die Blood, May 1, 2006; 107(9): 3422 - 3423. [Full Text] [PDF]

				F. Passamonti, E. Rumi, D. Pietra, M. G. D. Porta, E. Boveri, C. Pascutto, L. Vanelli, L. Arcaini, S. Burcheri, L. Malcovati, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders Blood, May 1, 2006; 107(9): 3676 - 3682. [Abstract] [Full Text] [PDF]

				A. Zeuner, F. Pedini, M. Signore, G. Ruscio, C. Messina, A. Tafuri, G. Girelli, C. Peschle, and R. De Maria Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells Blood, May 1, 2006; 107(9): 3495 - 3502. [Abstract] [Full Text] [PDF]

				A. V. Jones, R. T. Silver, K. Waghorn, C. Curtis, S. Kreil, K. Zoi, A. Hochhaus, D. Oscier, G. Metzgeroth, E. Lengfelder, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha Blood, April 15, 2006; 107(8): 3339 - 3341. [Abstract] [Full Text] [PDF]

				A. Tefferi, M. A. Elliott, and A. Pardanani Atypical Myeloproliferative Disorders: Diagnosis and Management Mayo Clin. Proc., April 1, 2006; 81(4): 553 - 563. [Abstract] [Full Text] [PDF]

				S. Ghaffari, C. Kitidis, W. Zhao, D. Marinkovic, M. D. Fleming, B. Luo, J. Marszalek, and H. F. Lodish AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation Blood, March 1, 2006; 107(5): 1888 - 1891. [Abstract] [Full Text] [PDF]

				M. Sattler, C. Walz, B. J. Crowley, E. Lengfelder, P. A. Janne, A. M. Rogers, Y. Kuang, R. J. Distel, A. Reiter, and J. D. Griffin A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples Blood, February 1, 2006; 107(3): 1237 - 1238. [Full Text] [PDF]

				W. Zhao, C. Kitidis, M. D. Fleming, H. F. Lodish, and S. Ghaffari Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway Blood, February 1, 2006; 107(3): 907 - 915. [Abstract] [Full Text] [PDF]

				E. M. Adler, N. R. Gough, and L. B. Ray 2005: Signaling Breakthroughs of the Year Sci. Signal., January 3, 2006; 2006(316): eg1 - eg1. [Abstract] [Full Text] [PDF]

				R. L. Levine and G. Wernig Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders Hematology, January 1, 2006; 2006(1): 233 - 239. [Abstract] [Full Text] [PDF]

				A. Tefferi Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era Hematology, January 1, 2006; 2006(1): 240 - 245. [Abstract] [Full Text] [PDF]

				J. Staerk, A. Kallin, J.-B. Demoulin, W. Vainchenker, and S. N. Constantinescu JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: CROSS-TALK WITH IGF1 RECEPTOR J. Biol. Chem., December 23, 2005; 280(51): 41893 - 41899. [Abstract] [Full Text] [PDF]

				J. Jelinek, Y. Oki, V. Gharibyan, C. Bueso-Ramos, J. T. Prchal, S. Verstovsek, M. Beran, E. Estey, H. M. Kantarjian, and J.-P. J. Issa JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood, November 15, 2005; 106(10): 3370 - 3373. [Abstract] [Full Text] [PDF]

				R. L. Levine, M. Loriaux, B. J. P. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia Blood, November 15, 2005; 106(10): 3377 - 3379. [Abstract] [Full Text] [PDF]

				M. Pesu, J. O'Shea, L. Hennighausen, and O. Silvennoinen Identification of an Acquired Mutation in Jak2 Provides Molecular Insights into the Pathogenesis of Myeloproliferative Disorders Mol. Interv., August 1, 2005; 5(4): 211 - 215. [Abstract] [Full Text] [PDF]

				W. Vainchenker and S. N. Constantinescu A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases Hematology, January 1, 2005; 2005(1): 195 - 200. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 280/24/22788    most recent C500138200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhao, R. Articles by Zhao, Z. J. Search for Related Content PubMed PubMed Citation Articles by Zhao, R. Articles by Zhao, Z. J. Social Bookmarking                      What's this?